Fly News Breaks for March 4, 2016
BLUE
Mar 4, 2016 | 08:45 EDT
Wells Fargo believes that interim data from a trial of bluebird's gene therapy candidate Lenti-D in cerebral adrenoleukodystrophy was positive. The firm thinks that the data "further validate" the company's gene therapy pipeline. It keeps an Outperform rating on the shares.
News For BLUE From the Last 2 Days